Z45.F ALVOTECH S.A.S

Healthcare Pharmaceuticals Frankfurt Exchange
4.01 EUR
Close of Nov 12, 2026
2.52 5.38
Market cap
EUR 1.43B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is Z45.F undervalued?

Graham number

The Graham number of ALVOTECH S.A.S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALVOTECH S.A.S fundamental analysis

No fundamental analysis for ALVOTECH S.A.S yet.

ALVOTECH S.A.S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALVOTECH S.A.S

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis…

Full company profile